Scienture Holdings Board Restructures After Director Resignations

TipRanksJan 17 16:29 ET

Scienture Holdings Faces Nasdaq Compliance Challenge

TipRanksJan 8 17:19 ET

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

GlobeNewswireDec 17, 2024 08:05 ET

Scienture, LLC Receives New Patent for SCN-102, Expanding Intellectual Property for Innovative Losartan Liquid Formulation

Quiver QuantitativeDec 10, 2024 08:13 ET

Scienture, LLC, a Wholly Owned Subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering Its First Product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) Through 2041

GlobeNewswireDec 10, 2024 08:05 ET

Express News | Scienture, LLC, a Wholly Owned Subsidiary of Scienture Holdings, Inc. (Nasdaq: Scnx) Announces Issuance of a New Patent Covering Its First Product Scn-102 (Losartan Potassium Oral Suspension, 10Mg/Ml) Through 2041

ReutersDec 10, 2024 08:05 ET